Effect of dietary supplementation with a new nutraceutical formulation on cardiometabolic risk factors: a double-blind, placebo-controlled, randomized clinical study

Introduction The scientific community and consumers are increasingly interested in the potential cholesterol-lowering effect of various nutraceuticals their combinations. aim our study was to test short-term a new lipid-lowering nutraceutical formulation mildly hypercholesterolemic patients. Material methods We consecutively enrolled 80 patients with low-density lipoprotein-cholesterol (LDL-C) between 130 190 mg/dl low-estimated cardiovascular disease risk. After 8 week-stabilization diet, subjects were randomized take 1 pill/evening Zeta Colest (including: 400 mg Berberis aristata dry extract 340 berberine, 98 red yeast rice 2.9 total monacolins, 87.5 milk thistle 70 silymarin, 50 guggul 1.3 guggulsterones) or placebo for weeks. Patients followed up metabolic haemodynamic parameters. Results week-supplementation tested combined nutraceuticals, we observed significant reduction cholesterol (–16.7 ±1.5%), LDL-C (–18.1 ±1.9%), non-high-density lipoprotein (–19.2 ±2.1%), apoB (–20.7 ±2.3%) high-sensitivity C-reactive protein (–3.0 ±0.6%), versus both baseline (p < 0.05) control group 0.05). No other liver parameters significantly changed during observation period. Endothelial reactivity also but improved by 2.96 ±0.23% product. Conclusions In short term, lipid metabolism, systemic inflammation vascular function overweight subjects.